Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 9/20 | 0.51 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.38 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044029 | 0.98 | LPAR3 (0.50) | LPAR3LPAR1LPAR5ENPP2LPAR2 | |
| SCHEMBL9972139 | 0.94 | LPAR3 (0.57) | LPAR3LPAR1LPAR5ENPP2LPAR2 | |
| SCHEMBL9972138 | 0.90 | LPAR3 (0.54) | LPAR3LPAR1LPAR5ENPP2LPAR2 | |
| SCHEMBL10044028 | 0.84 | LPAR3 (0.49) | LPAR3LPAR1LPAR5ENPP2PLA2G2C | |
| SCHEMBL9972146 | 0.83 | ENPP2 (0.47) | LPAR3LPAR1LPAR5ENPP2LPAR2 | |
| SCHEMBL888509 | 0.82 | PGK1 (0.48) | LPAR3LPAR1ENPP2SMN1; SMN2 | |
| SCHEMBL5594633 | 0.81 | LPAR3 (0.77) | LPAR3LPAR1LPAR5ENPP2LPAR2 | |
| SCHEMBL4948840 | 0.81 | LPAR3 (0.77) | LPAR3LPAR1LPAR5ENPP2LPAR2 | |
| SCHEMBL1191674 | 0.81 | LPAR3 (0.77) | LPAR3LPAR1LPAR5ENPP2LPAR2 | |
| SCHEMBL9972142 | 0.80 | ENPP2 (0.43) | LPAR3LPAR1ENPP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9251937-B2 | Heat stable nanoparticle preparations and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2016-02-02 | — | — | US | disclosed |
| US-8895068-B2 | Nanoparticle composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889103-B2 | Diagnostic agent composition and associated methods thereof | GENERAL ELECTRIC COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | GENERAL ELECTRIC COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156142-A1 | DIAGNOSTIC AGENT COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PHAX, PIK3CA | LPAR3 972/4885LPAR1 1795/4885LPAR5 1799/4885 |
| US-20120156141-A1 | NANOPARTICLE COMPOSITION AND ASSOCIATED METHODS THEREOF | PHOSPHO1, PIK3CA, PTEN | LPAR3 789/4885LPAR1 1554/4885LPAR5 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.